Key statistics
As of last trade Emergent BioSolutions Inc (ER4:MUN) traded at 8.31, -36.78% below its 52-week high of 13.15, set on Jul 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.31 |
---|---|
High | 8.31 |
Low | 8.31 |
Bid | 8.31 |
Offer | 8.48 |
Previous close | 8.27 |
Average volume | 7.69k |
---|---|
Shares outstanding | 54.02m |
Free float | 52.87m |
P/E (TTM) | -- |
Market cap | 498.06m USD |
EPS (TTM) | -11.24 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 07:04 BST.
More ▼
Announcements
- Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
- Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
- Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
- Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
- Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
- Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
- Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
- Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
- Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
- Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
More ▼